US equities |
MU $911.64 ▼-0.27% NVDA $217.61 ▼-1.67% SNDK $1,342.52 ▼-4.33% SPCX $146.69 ▼-3.59% AMD $548.75 ▼-3.87% INTC $94.03 ▼-4.16% AAPL $344.76 ▲+0.53% TSM $418.86 ▼-2.59%
FinancialContent

Entera Bio Ltd. - Ordinary Shares (NQ:ENTX)

2.625 +0.125 (+5.00%)
Delayed Quote Updated: 1:15 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Entera Bio Ltd. - Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting
From Entera Bio Ltd.
Via GlobeNewswire
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
Former Gilead and Amgen executive joins Entera with over 35 years of experience advancing and commercializing impactful and blockbuster therapies 
From Entera Bio Ltd.
Via GlobeNewswire
Entera Bio (NASDAQ:ENTX) Slides on Wider Q2 Loss Despite FDA Phase 3 Alignment and $275M Cash Raise ↗
Via Chartmill
News headline image
Correction: Entera to Participate in Upcoming Fall Investor Conferences
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera to Participate in Upcoming Fall Investor Conferences
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement ↗
Entera Bio (NASDAQ:ENTX) plans to begin a Phase 3 study of its oral osteoporosis candidate EB613 after reaching agreement with the U.S. Food and Drug Administration on a 12-month, placebo-controlled... 
Via MarketBeat
News headline image
Entera Announces Second Quarter 2026 Financial Results and Business Updates
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
From Entera Bio Ltd.
Via GlobeNewswire
Which stocks are moving on Monday? ↗
Via Chartmill
Curious about the most active stocks on Monday? ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers Entera Bio (NASDAQ:ENTX) stock moved upwards by 86.6% to $3.83 during Monday's regular session. The company's market cap stands at $100.9 million. Gossamer Bio (NASDAQ:GOSS) shares moved... 
Via Benzinga
Monday's session: top gainers and losers ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
From Entera Bio Ltd.
Via GlobeNewswire
What's going on in today's after hours session ↗
Via Chartmill
Top movers analysis one hour before the close of the markets on 2026-06-22: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
From Entera Bio Ltd.
Via GlobeNewswire
Get insights into the top gainers and losers of Friday's after-hours session. ↗
Via Chartmill
News headline image
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
ENTX Rallies As Insiders Buy Company Shares — Retail Hopes For ‘Exciting Days’ Ahead ↗
Entera Bio said that the company chairman Geno J. Germano bought shares, in addition to directors Steven D. Rubin, Haya Taitel, and Sean Ellis. 
Via Stocktwits
Big Pharma Just Put Peptides Back on the Map – Which Players Are Still Under the Radar?
Via AB Newswire
< Previous 1 2 3 4 Next >